Truvada (Tenofovir/FTC)
| Brand Name: |
Truvada |
| Generic Name: |
Emtricitabine + tenofovir disoproxil
fumarate, FTC/TDF |
| Adult Single Dose: |
One tablet containing 200 mg FTC
and 300 mg TDF (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
|
|
|
The Basics
- FAQs About Truvada (Tenofovir/FTC) From The Body's "Ask the Experts" Forums (Regularly Updated)
From The Body's "Ask the Experts" Forums
- Patient Assistance Programs (Regularly Updated)
Having problems paying for Truvada? Visit Gilead's patient assistance program page.
From Gilead Sciences, Inc.
- An Overview of Truvada (Tenofovir/FTC) (November 4, 2011)
From AIDSinfo
- Truvada (Tenofovir + Emtricitabine) (August 4, 2011)
To read PDF, click here.
From AIDS InfoNet
- Patient Information About Truvada (Tenofovir/FTC) (PDF) (July 2011)
From Gilead Sciences, Inc.
- CDC Trials: Pre-Exposure Prophylaxis for HIV Prevention (February 2011)
To read PDF, click here.
From U.S. Centers for Disease Control and Prevention
- Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: Promoting Safe and Effective Use in the United States (February 2011)
To read PDF, click here.
From U.S. Centers for Disease Control and Prevention
- Truvada (March/April 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Truvada (Viread + Emtriva) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
[Archived Article]
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
[Archived Article]
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
News
- Gilead Seeks First-Ever Approval for Drug to Prevent HIV (December 16, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead Submits Application to FDA Asking for PrEP Approval for Truvada (December 16, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- HIV PJA Strategy Webinar Recap: FEM-PrEP Trial Closure, U.S. Pricing & Access Issues After iPrEx, & UN Update (April 21, 2011)
From HIV Prevention Justice Alliance
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
- Gilead's $12,000-a-Year HIV Prevention Pill Fails to Win Physician Support (March 3, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New Combo Pill Submitted to FDA (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- MedPage Today Examines Recent Developments, Trials Underway in HIV Prevention (December 24, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Illinois: Project PrEPare, AIDS Foundation of Chicago Hold HIV Drug Forum (December 23, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Utahns Don't Expect Swift Widespread Use of AIDS Pill That Helps Gay Men Avoid HIV Infection (December 22, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- California: Preventive Drug Brings Promise -- and Questions (December 13, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- After HIV Pill News, Now Comes the Tricky Part (December 8, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Hold the Celebrations: Antiretroviral Drugs Not Promised to Prevent HIV: A Blog Entry by Candace Y.A. Montague (November 28, 2010)
"Pills are great and the news of a new potential prevention method is still wonderful. But getting groups of people to see that they are at risk remains to be the challenge."
From The Body
- NIH-Funded Study Finds Daily Dose of Antiretroviral Drug Reduces Risk of HIV (November 23, 2010)
From AIDS.gov
- President Obama Welcomes New HIV Prevention Research Results (November 23, 2010)
From AIDS.gov
- A Pill to Prevent HIV? What the New iPrEx Results Mean for Women: A Blog Entry by Anna Forbes (November 23, 2010)
From RH Reality Check
- Gilead Sciences, Tibotec to Develop Second Once-Daily HIV Treatment (July 17, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
[Archived Article]
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
Research
- Global Campaign for Microbicides Statement on the Discontinuation of the FEM-PrEP Trial (April 19, 2011)
From Global Campaign for Microbicides
- Researchers to Wind Down HIV Prevention Trial in Women After Interim Results Find Drug Not Offering Protection From HIV (April 19, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Scientists Halt FEM-PrEP Study in Africa (April 18, 2011)
In Housing Works AIDS Issues Update, from Housing Works
- The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research (April 18, 2011)
From U.S. National Institute of Allergy and Infectious Diseases
- Results of FEM-PrEP Clinical Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Heterosexual Women (April 18, 2011)
From U.S. Centers for Disease Control and Prevention
 PrEP Ineffective for Women? Study on Truvada for HIV Prevention Is Unexpectedly Cut Short: A Blog Entry by Myles Helfand (April 18, 2011)
From The Body
- Once-a-Day Truvada Lowers HIV Risk in Gays and Transgender Women (March 2011)
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
- Gilead Sciences Receives "Refuse to File" Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada and TMC278 (January 25, 2011)
From Gilead Sciences, Inc.
- iPrEx: A Tenofovir/Emtricitabine Pill a Day Keeps the HIV (Doctor) Away (December 8, 2010)
Part of "Top HIV/AIDS-Related Clinical Developments of 2010," by David Wohl, M.D.
From The Body
- PrEP: What Does It Mean for Women? (December 8, 2010)
From Global Campaign for Microbicides
- Questions and Answers: Global Pre-Exposure Prophylaxis Initiative (iPrEx) Study (December 8, 2010)
From Global Campaign for Microbicides
- Taken Preventively Daily HIV Meds Could Reduce HIV Risk Among Gay, Bisexual Men (November 30, 2010)
From Black AIDS Institute
- Chicago-Based Pre-Exposure Prophylaxis Study Team Responds to Recent iPrEx Study Results (November 29, 2010)
From Project PrEPare
- CDC Statement on Results of iPrEx Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex With Men (November 23, 2010)
From U.S. Centers for Disease Control and Prevention
- Global Campaign for Microbicides Lauds Milestone in HIV Prevention Findings That Daily Use of Anti-Retroviral Protects Against HIV Infection (November 23, 2010)
Results from global iPrEx trial offer hope for those at highest risk of infection.
From Global Campaign for Microbicides
- The Future of PrEP: Questions and Next Steps Following the iPrEx Study Results (November 23, 2010)
From Project Inform
- Daily Oral Antiretroviral Reduces HIV Infection Risk in MSM by 44%, Study Finds (November 23, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
 iPrEx: First-Ever PrEP Efficacy Study Published (November 23, 2010)
Paul Sax, M.D., offers his analysis of the study results and their real-world implications.
From Journal Watch
- Daily Dose of Truvada Reduces HIV Infection Risk by 44 Percent Among Gay Men, Study Finds (November 23, 2010)
From U.S. National Institute of Allergy and Infectious Diseases
- Small Study Suggests Once-Daily MVC Plus ATV/r as Viable First Regimen (July 26, 2010)
From National AIDS Treatment Advocacy Project
- ACTG 5202: Four Drugs Enter (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- High Rate of Coronary Artery Problems in Young People Tied to TDF/FTC (February 18, 2010)
From National AIDS Treatment Advocacy Project
- ACTG 5202: No Significant Difference in Time to Failure Between Kivexa and Truvada in Patients With Lower Viral Loads When Paired With Efavirenz or Atazanavir (February 18, 2010)
From aidsmap.com
- Serious Non-AIDS Health Problems (Especially Heart Problems) Appear Less Likely With Truvada Than Epzicom, But Low Bone Mineral Density Is More Likely, Switch Study Finds (October 20, 2009)
In Clinical Infectious Diseases
- Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds (February 9, 2009)
Walid Heneine, Ph.D., explains the results of a study in macaques which found that a topical gel offered complete protection against SIV infection -- regardless of whether that gel contained tenofovir alone or tenofovir in combination with emtricitabine.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- HIV JournalView: Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz (February/March 2006)
An important study by Joel Gallant et al demonstrates the advantage of tenofovir + FTC in first-line therapy.
From The Body PRO
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here.
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows? (December 2004)
[Archived Article]
A highly critical examination of the manner in which many clinical trials are designed.
In TAGline, from Treatment Action Group
- Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
[Archived Article]
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group
|
|
Advertisement
|
Email
Glossary
